AN2 Therapeutics, Inc.

For the period ended Dec 31, 2025. Filed Mar 17, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 17, 2026

ANTX$4.33+8.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Balance Sheets as of December 31, 2025 and 2024

BALANCE SHEETS

	December 31,	December 31,
	2025	2024
Assets
Current assets:
Cash and cash equivalents	$19,941	$21,351
Short-term investments	38,060	62,267
Prepaid expenses and other current assets	1,936	2,644
Total current assets	59,937	86,262
Long-term investments	2,013	5,021
Other assets, long-term	—	804
Total assets	$61,950	$92,087
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$3,021	$3,317
Accrued compensation	2,418	1,676
Accrued liabilities	2,052	4,454
Other current liabilities	1,229	791
Total current liabilities	8,720	10,238
Other non-current liabilities	170	—
Total liabilities	8,890	10,238
Commitments and contingencies (Note 7)
Stockholders’ equity:
Preferred stock, $0.00001 par value; 10,000,000 shares authorized at December 31, 2025 and December 31, 2024; no shares issued and outstanding at December 31, 2025 and December 31, 2024	—	—
Common stock, $0.00001 par value; 500,000,000 shares authorized at December 31, 2025 and December 31, 2024; 27,413,171 and 29,919,634 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively	—	—
Additional paid-in capital	293,953	287,594
Accumulated other comprehensive gain	57	31
Accumulated deficit	(240,950)	(205,776)
Total stockholders’ equity	53,060	81,849
Total liabilities and stockholders’ equity	$61,950	$92,087

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.